Kashiv BioSciences News and Activities

Acquisition, funding and merger involving Kashiv BioSciences.

• Amneal Pharmaceuticals has announced the acquisition of Kashiv BioSciences  (posted on April 22 2026).
• Kashiv BioSciences has just announced a $150 Million fundraising (posted on April 7 2025).

View the org chart displaying its 15 main executives

Most searched biographies at Kashiv BioSciences

• Sandeep Athalye, Global Chief Executive Officer
• Chirag Patel, Executive Chairman and Co-Founder
• Viet Nguyen, Chief Operating Officer

Popular executive movements at Kashiv BioSciences

• Ravishankar Kasturi has joined the company as Head of Operations, India  (posted on April 24 2026).
• Arlene Wolny has joined the company as Senior Vice President of Regulatory Affairs  (posted on April 15 2026).
• Viet Nguyen has joined the company as Chief Operating Officer  (posted on April 15 2026).

Click here to view some more movements at Kashiv BioSciences

Create your alert
to follow the executive moves at Kashiv BioSciences.

Kashiv BioSciences has 2,430 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Tempus has announced the acquisition of Personalis  (posted on July 20 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (posted on July 17 2026).
• GSK has acquired Nuvalent (posted on July 17 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Kashiv BioSciences

• Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer
• Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
• Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO
• Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)

Social media about Kashiv BioSciences

• Kashiv BioSciences on Wikipedia, Google News & Yahoo Finance
• Kashiv BioSciences on LinkedIn, X (Twitter) & YouTube